Navigating toxicities in BCMA-directed multiple myeloma therapy

In recent years, the treatment landscape for multiple myeloma has undergone a profound transformation, particularly with the emergence of B-cell maturation antigen (BCMA)-targeted therapies, which are providing unprecedented results. This eBook explores the new clinical challenges that BCMA therapies present, including how to expand post CAR T-cell therapy relapse options. Download the eBook for practical guidance on managing side effects such as immune effector cell-associated hematotoxicity and insights on integrating these novel immunomodulatory agents into clinical practice. Contents: Conference report: A hematologist’s guide to the most important abstracts at ASCO 2026 Editorial: How to manage prolonged immune effector cell-associated hematotoxicity...